Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025)
Sunshine Biopharma's (SBFM) quarterly Asset Writedowns and Impairment came in at $131788.0 in Q4 2025, down 76.24% on a QoQ basis from $554650.0 in Q3 2025.
Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025) Analysis & Trends
Sunshine Biopharma (SBFM) has 1 years of Asset Writedowns and Impairment data on file, last reported at $131788.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $131788.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to $131788.0 in Q4 2025, from $554650.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.1 million in Q2 2025 to a low of $131788.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 131,788.00 |
| Dec 31, 2025 | 131,788.00 |
| Sep 30, 2025 | 554,650.00 |
| Sep 30, 2025 | 554,650.00 |
| Jun 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.06 Mn |